AMT Medical, a clinical-stage medtech innovator, has secured $25 million in Series B funding to advance its minimally invasive, sutureless coronary artery bypass solution. The round was led by Bender Analytical Holding B.V. (BAH). With new investors Invest-NL and the European Innovation Council (EIC) joining existing backers Oost NL and several angel investors. Including this round and multiple grants from RvO and the EIC Accelerator, AMT has raised a total of $40 million.
AMT Medical is developing the ELANA® Heart Bypass System, a technology designed to offer a safer, faster. And more cost-effective alternative to traditional coronary artery bypass grafting (CABG). The ELANA system enables robot-assisted keyhole surgery through small incisions, reducing trauma, cost, and recovery time. The latest funding will support CE marking efforts, the launch of clinical trials in both open and robotic settings in the United States, and completion of ongoing European studies.
CEO and Co-Founder Rutger Tulleken stated, “This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes but redefining cardiovascular care.”
AMT is conducting a first-in-human European trial of the ELANA system for beating-heart CABG procedures. Results are expected by late 2025, with plans to obtain CE marking by 2026 for procedures via sternotomy or minimally invasive thoracotomy. The company will also initiate U.S. clinical trials for both robotic and open applications.
Founded in 2017 and based in Ede and Utrecht, the Netherlands, AMT Medical was inspired by a neurosurgical technique developed by Tulleken’s father. This method has now been adapted for heart procedures to reduce patient trauma and recovery time.
The ELANA system replaces complex suturing with a sutureless anastomosis technique using a proprietary clip and excimer laser. This allows for standardised graft integration, reduced complications, and over 50% cost savings in robotic settings. By enabling CABG without stopping the heart or using a heart-lung machine, it also reduces stroke risk and hospital stays.
Globally, over one million CABG procedures are performed each year, and the market is expected to exceed $2.5 billion by 2027. Most of these surgeries still rely on invasive techniques. AMT’s innovation could redefine the standard of care and reduce the burden on healthcare systems.
Johan Bender, CEO of Bender Analytical Holding, said, “We are proud to support AMT as they work toward FDA clearance to bring their technology to the market in the U.S. This marks a key milestone in improving patient outcomes.”
With regulatory milestones ahead and growing investor support, AMT Medical is poised to transform the future of heart surgery.
